You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

201 search results for: type 2 inflammation

Itch: The Common Thread in Dermatological <b>Type</b> <b>2</b> <b>Inflammation</b> (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
Itch: The Common Thread in Dermatological <b>Type</b> <b>2</b> <b>Inflammation</b> (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
The Impact of <b>Type</b> <b>2</b> <b>Inflammation</b> on the Neuroimmune Axis in AD
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
View more
FeNO: A Biomarker of <b>Type</b> <b>2</b> <b>Inflammation</b> in Pediatric Asthma Patients
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Pulmonology
Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma
View more
The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Multiple Disease Trajectories
Infographic

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Dermatology
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.
View more
Potential Role of Type 2 Inflammation in the Pathogenesis of CSU
expert video

Potential Role of Type 2 Inflammation in the Pathogenesis of CSU

Dermatology
Join Professor Hide as he describes the potential role of Type 2 inflammation in the pathogenesis of CSU.
View more
Why targeting <b>Type</b> <b>2</b> <b>Inflammation</b> is important in the treatment of skin diseases like AD, PN and CSU
expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Dermatology
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
View more
A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Infographic

A Triad of Interacting Mechanisms Driving the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Type 2 Inflammation
Discover how barrier dysfunction, neuroimmune dysregulation, and type 2 inflammation contribute to the pathophysiology of various diseases
View more
Skin Barrier Dysfunction and <b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis
videoanimation

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Dermatology
Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IcelandChange country/region